Srinivas Gullapalli

This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Glenmark Pharmaceuticals S.a.. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srinivas Gullapalli. Retrieved from https://idiyas.com/inventor/srinivas-gullapalli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

4 out of 65

Glenmark Pharmaceuticals S.a.

patents

Years Active: 2011-2017

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9532988 - Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent (2017-01-03),

2. 8420689 - Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation (2013-04-16),

3. 7951814 - Quinazolinedione derivatives as TRPA1 modulators (2011-05-31),

4. 7923465 - Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation (2011-04-12),

Title: The Innovative Contributions of Srinivas Gullapalli

Introduction

Srinivas Gullapalli is a notable inventor based in Navi Mumbai, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that target pain management and cannabinoid receptor modulation. With a total of 4 patents to his name, his work reflects a commitment to advancing medical science.

Latest Patents

Gullapalli's latest patents include a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. This patent application focuses on a composition that utilizes a thienopyrimidinedione compound as a TRPA1 antagonist, aimed at treating pain in subjects. Another significant patent involves cannabinoid receptor ligands, which are novel modulators for cannabinoid receptors, specifically CB1 and CB2. This invention outlines the use of these modulators for treating various diseases and conditions influenced by cannabinoid receptors.

Career Highlights

Srinivas Gullapalli is currently associated with Glenmark Pharmaceuticals S.A., where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing effective treatments that leverage the latest scientific discoveries.

Collaborations

Gullapalli has collaborated with esteemed colleagues such as Meyyappan Muthuppalaniappan and Gopalan Balasubramanian, contributing to a dynamic research environment that fosters innovation.

Conclusion

Srinivas Gullapalli's contributions to pharmaceutical innovations demonstrate his dedication to improving healthcare through scientific advancements. His patents reflect a forward-thinking approach to pain management and cannabinoid research, marking him as a significant figure in the field.

Profile summary based on public USPTO records.